For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 4,911 | 8,283 | 3,603 | 5,806 |
| General and administrative | 2,140 | -1,297 | 2,335 | 3,063 |
| Total operating expenses | 7,051 | 6,986 | 5,938 | 8,869 |
| Loss from operations | -7,051 | -9,555 | -5,938 | -8,869 |
| Other income (expense), net | - | -2,586* | - | 12,659 |
| Interest income | 247 | 193* | 411 | 377 |
| Net loss | -6,804 | -11,948 | -5,527 | 4,167 |
| Unrealized (loss) gain on short-term investments | -7 | 3 | 20 | -15 |
| Comprehensive loss | -6,811 | -11,945 | -5,507 | 4,152 |
| Basic EPS | -0.73 | -1.61 | -0.59 | 0.51 |
| Diluted EPS | -0.73 | -1.535 | -0.59 | -1 |
| Basic Average Shares | 9,381,344 | 7,419,060* | 9,377,079 | 8,246,582 |
| Diluted Average Shares | 9,381,344 | 7,783,182* | 9,377,079 | 8,455,223 |
Tvardi Therapeutics, Inc. (TVRD)
Tvardi Therapeutics, Inc. (TVRD)